Hospital Pharmacy - June 2017 - 407

407

Walker
Table 1. CGRP Receptor Antagonists in Development
Generic name

Sponsor

Proposed administration

Comments

Eptinezumab

Alder Biopharmaceuticals

IV infusion every 3 months

Erenumab

Amgen, Novartis
Pharmaceuticals

Monthly subcutaneous
injection

Fremanezumab

Teva Pharmaceutical
Industries, Ltd

Monthly subcutaneous
injection

Galcanezumab

Eli Lilly and Co

Atogepant

Allergan

Monthly subcutaneous
injection
Oral

Alder announced that in the 888-patient, 56-week, phase
3, PROMISE 1 trial, eptinezumab reduced monthly
migraine days by 1 day compared with placebo.
Amgen has filed a BLA with a PDUFA date of 7/17/18.
Presentations of data from the 955-patient STRIVE
study and the 577-patient ARISE study demonstrated
a 1-2 day decrease in monthly migraine-free days
compared with placebo.
Fremanezumab reduced monthly migraine days in 2
phase 2 trials. Teva announced that in a 1130-patient,
16-week, phase 3 trial (HALO chronic migraine study),
fremanezumab reduced monthly migraine days by 2
days with both a 1- and 3-month dosing regimen.
Galcanezumab decreased monthly migraine days by 2
days in phase 2 and 3 trials.
A small molecule that potentially may be the first oral
CGRP receptor inhibitor.

Note. Information adapted from the Prescribe Right Pharmaceutical Pipeline Tracker database. CGRP = calcitonin gene-related peptide; IV = intravenous;
BLA = biologics license application; STRIVE = STudy to evaluate the efficacy and safety of erenumab in migRaIne preVEntion; ARISE = A phase 3,
RandomIzed, double-blind, placebo-controlled Study to Evaluate the efficacy and safety of erenumab in migraine prevention; HALO = per a letter from
Teva Pharmaceutical, HALO has no special meaning; PROMISE = PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy;
PDUFA = Prescription Drug User Fee Act.

data may be utilized. The information provided is meant to
provide a way to assess the development status of a new drug
and should not be used in making patient care decisions.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1.

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML,
Stewart WF. Migraine prevalence, disease burden, and the
need for preventive therapy. Neurology. 2007;68:343-349.

Goldberg LD. The cost of migraine and its treatment. Am J
Manag Care. 2005;11(2 suppl):S62-S67.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346:257-270.
Puledda F, Messina R, Goadsby PJ. An update on migraine:
current understanding and future directions [published online
ahead of print March 20, 2017]. J Neurol. doi:10.1007/s00415017-8434-y.
Adams B. Teva posts positive phase 3 migraine data, plots
FDA submission. FierceBiotech. http://www.fiercebiotech.
com/biotech/teva-posts-positive-phase-3-migraine-data-plotsfda-submission. Published May 31, 2017. Accessed July 11,
2017.
Silbestein SD, Tepper SJ. Updates in the clinical science of
CGRP antagonism for the treatment of migraine. Medscape.
http://www.medscape.org/viewarticle/867852_transcript.
Published 2016. Accessed May 31, 2017.

http://www.fiercebiotech.com/biotech/teva-posts-positive-phase-3-migraine-data-plots-fda-submission http://www.fiercebiotech.com/biotech/teva-posts-positive-phase-3-migraine-data-plots-fda-submission http://www.fiercebiotech.com/biotech/teva-posts-positive-phase-3-migraine-data-plots-fda-submission http://www.medscape.org/viewarticle/867852_transcript

Table of Contents for the Digital Edition of Hospital Pharmacy - June 2017